Innovent Biologics (HKG:1801) recorded an attributable profit of 834.3 million yuan in the first half of 2025, compared with an attributable loss of 392.6 million yuan a year prior, a Wednesday filing with the Hong Kong bourse said.

Earnings per share stood at 0.49 yuan in the six months, while the company incurred a loss per share of 0.24 yuan in the corresponding period of the last year.

Revenue for the drug company from contracts with customers rose 51% to 5.95 billion yuan in the half year from 3.95 billion yuan in the year-ago period.

The higher revenue was driven by strong performance in oncology products, the expansion of the general biomedicine portfolio, and a rise in license fee income.

The firm attributed the turnaround to profit mainly to strong revenue growth and a boost in operational efficiency.